Revestive (teduglutide)

pCPA File Number: 20950

Negotiation Status:

Concluded with an LOI

Indication(s):

Short Bowel Syndrome (SBS)

Sponsor/Manufacturer:

Shire Pharma Canada ULC

CDA-AMC Project Number:

SR0459-000

pCPA Engagement Letter Issued:

2017-06-30

Negotiation Process Concluded:

2018-08-07